HomeInsightsStock Comparison

Kilitch Drugs India Ltd vs Oxygenta Pharmaceutical Ltd Stock Comparison

Kilitch Drugs India Ltd vs Oxygenta Pharmaceutical Ltd Stock Comparison

Last Updated on: May 17, 2026

Key Highlights

  • The Latest Trading Price of Kilitch Drugs (India) Ltd is ₹ 153 as of 15 May 15:30 . The P/E Ratio of Kilitch Drugs (India) Ltd changed from 34.2 on March 2021 to 21.8 on March 2025 . This represents a CAGR of -8.61% over 5 yearsThe P/E Ratio of Oxygenta Pharmaceutical Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Kilitch Drugs (India) Ltd changed from ₹ 125.58 crore on March 2021 to ₹ 581.3 crore on March 2025 . This represents a CAGR of 35.86% over 5 yearsThe Market Cap of Oxygenta Pharmaceutical Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Kilitch Drugs (India) Ltd for the Mar '26 is ₹ 90.1 crore as compare to the Dec '25 revenue of ₹ 55.34 crore. This represent the growth of 62.81% The revenue of Oxygenta Pharmaceutical Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Kilitch Drugs (India) Ltd for the Mar '26 is ₹ 22.64 crore as compare to the Dec '25 ebitda of ₹ 7.68 crore. This represent the growth of 194.79% The ebitda of Oxygenta Pharmaceutical Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Kilitch Drugs (India) Ltd changed from ₹ 0.11 crore to ₹ 14.88 crore over 8 quarters. This represents a CAGR of 1063.07% The net profit of Oxygenta Pharmaceutical Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Kilitch Drugs (India) Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Oxygenta Pharmaceutical Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Kilitch Drugs (India) Ltd

  • Kilitch Drugs (India) Limited (KDIL), incorporated in May, 1992 is the one of the leading and fastest growing pharmaceutical companies in the world, manufacturing, supplying and marketing broad range of pharmaceutical formulations in the various dosage forms like Solid, Liquid and Parental across the globe.
  • Their extensive research efforts have led to development of comprehensive, diverse and highly complementary portfolio of medicines targeting a wide spectrum of chronic and acute treatments which includes Sterile dosages namely Injectables & Ophthalmic, Effervescent tablets & Granules, Tablets & Capsules, OTC range covering varied Nutraceuticals & Cosmetics and Medical devices. The Company is engaged in development, manufacturing and marketing of quality finished dosages.
  • The Company is one of the most reliable manufacturer of injectables in India and one of the largest manufacturer of cephalosporins in Africa having its manufacturing unit located in India and Ethiopia.

About Oxygenta Pharmaceutical Ltd

  • Oxygenta Pharmaceutical Limited was initially incorporated as S S Organics Private Limited as a private limited Company in 1990.
  • The Company converted its status to a Public Limited Company in 1993 changing the name to S S Organics Limited.
  • Further, it was changed to Oxygenta Pharmaceutical Limited in FY 2021-22. The Company was incorporated with the objective of carrying on the business of manufacturing all classes and kinds of Drugs including Pharmaceutical preparation, and Organic Fine Chemicals.
  • It manufactures a wide range of new generation quinolones, antiasthmatic, antiulcerant, and anti-inflammatory drugs.
  • The Company has plant located at Medak in Andhra Pradesh. The Company is strong in manufacturing of anti ulcerative and anti bacterial drugs.

FAQs for the comparison of Kilitch Drugs (India) Ltd and Oxygenta Pharmaceutical Ltd

Which company has a larger market capitalization, Kilitch Drugs (India) Ltd or Oxygenta Pharmaceutical Ltd?

Market cap of Kilitch Drugs (India) Ltd is 534 Cr while Market cap of Oxygenta Pharmaceutical Ltd is 205 Cr

What are the key factors driving the stock performance of Kilitch Drugs (India) Ltd and Oxygenta Pharmaceutical Ltd?

The stock performance of Kilitch Drugs (India) Ltd and Oxygenta Pharmaceutical Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Kilitch Drugs (India) Ltd and Oxygenta Pharmaceutical Ltd?

As of May 17, 2026, the Kilitch Drugs (India) Ltd stock price is INR ₹153.0. On the other hand, Oxygenta Pharmaceutical Ltd stock price is INR ₹55.54.

How do dividend payouts of Kilitch Drugs (India) Ltd and Oxygenta Pharmaceutical Ltd compare?

To compare the dividend payouts of Kilitch Drugs (India) Ltd and Oxygenta Pharmaceutical Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions